{"id":"W4385667677","doi":"10.1097/01.hs9.0000970376.71405.63","title":"P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Tolerability; Multiple myeloma; Daratumumab; Dexamethasone; Oncology; Gastroenterology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006688305,0.0005902768,0.001179909,0.0001953278,0.000171027,0.0006341067,0.0003996712,0.0005151734,0.002131292],"category_scores_gemma":[0.0004853904,0.0002886719,0.000955781,0.0003396528,0.0003250377,0.0003783146,0.0002856786,0.001503412,0.0004987015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006232062,"about_ca_system_score_gemma":0.0007457571,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008654324,"about_ca_topic_score_gemma":0.003764525,"domain_scores_codex":[0.999785,0.00008658723,0.00001704454,0.00004538073,0.00002089359,0.00004512972],"domain_scores_gemma":[0.9997726,0.00003174978,0.00006092254,0.00001398884,0.00001282619,0.0001079044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8114427,0.01029083,0.01655567,0.0009813803,0.002086196,0.0001993041,0.0002701728,0.002326862,0.02895062,0.0001432009,0.003602562,0.1231505],"study_design_scores_gemma":[0.5730565,0.3475213,0.06340848,0.0001209279,0.002630561,0.0005073666,0.0001223298,0.001336597,0.004591461,0.00020375,0.006460493,0.00004026902],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943233,0.003326532,0.0001225925,0.000267264,0.00004798694,0.0003737491,0.0006857323,0.00002860375,0.0008242379],"genre_scores_gemma":[0.9940467,0.002117089,0.0004398515,0.0003509594,0.00009485845,0.0003584693,0.001319801,0.000009309912,0.001263077],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002131292,"threshold_uncertainty_score":0.007129848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01946843014564231,"score_gpt":0.2564835981051531,"score_spread":0.2370151679595108,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}